Humacyte Inc (HUMA) saw downtrend of -8.11% in the recent trading with $1.02 being its most recent. The current price level -78.97% lower than the highest price of $4.85 marked by the stock while trading over the past 52-weeks, whereas it is 12.09% higher than the lowest price of $0.91 the company dropped to over past 52-weeks. The latest news story on HUMA appeared in (GlobeNewswire) under the title “Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 2 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.33 for the stock.
Humacyte Inc Earnings – What Happened With HUMA
Coming around sales and income figures on HUMA Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Humacyte Inc (HUMA) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of 18.00% for net revenue.
HUMA – Humacyte Inc Stock Earnings Estimates
The perspective of Humacyte Inc (NASDAQ:HUMA)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.25 for stock’s EPS in the current quarter. Humacyte Inc (HUMA) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of 18.00% for net revenue. Company’s EPS for the last quarter was -0.21.
Humacyte Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 193.00 million. HUMA does have institutional investors; and they hold 23.95% of the stock.
As on 2024-06-30, BLACKROCK INC. was the top most holder in Humacyte Inc (NASDAQ:HUMA) with an ownership of 7.14 million shares of the company or 5.9912 of the stake worth $34.27 million. The filing also reveals VANGUARD GROUP INC as the second largest holder in the company with a control over 3.9686 of the outstanding shares. Its stake is worth $22.7 million for having 4.73 million shares in hand.
STATE STREET CORP also came holding a key position in the company during the recent quarter and it now holds 2.4071 of the outstanding shares. With this there are now 180.0 institutions which have possession in HUMA’s shares.
